リコンビナントタンパク質＿精製したリコンビナントタンパク質 » リコンビナント成長因子 » GM-CSF, Human

GM-CSF, Human

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is produced by a number of different cell types, including activated T cells, B cells, macrophages, mast cells, endothelial cells, and fibroblasts, in response to cytokine of immune and inflammatory stimuli. Besides granulocyte-macrophage progenitors, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. On mature hematopoietic, monocytes/macrophages and eosinophils. Human Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) can induce human endothelial cells to migrate and proliferate. Additionally, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) can stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma, and adenocarcinoma cell lines.
Z00349
¥424,127.00

Ask us a question
Product Introduction
Species Human
Protein Construction

Expressed with an N-terminal Met.

GM-CSF (Ala18-Glu144)
Accession # P04141
Purity > 98% as analyzed by SDS-PAGE
> 98% as analyzed by SEC-HPLC
Endotoxin Level < 0.3 EU/μg of protein by gel clotting method
Biological Activity The ED50 as determined by the dose-dependant stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line) is less than 0.1 ng/ml, corresponding to a specific activity of 1.0 × 107 IU/mg.
Expression System E. coli
N-terminal Sequence Analysis The sequence of the first fifteen N-terminal amino acids was determined and found to be (Met)-Ala-Pro-Ala-Arg-Ser-Pro-Ser-Pro-Ser-Thr-Gln-Pro-Trp-Glu-His.
Apparent Molecular Weight ~14 kDa, on SDS-PAGE under reducing conditions.
Formulation Lyophilized after extensive dialysis against 20 mM phosphate buffer, pH7.0, 150 mM NaCl, 5% mannitol buffer.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile 18 MΩ-cm H₂O up to 100 µg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Background
Target Background Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is produced by a number of different cell types, including activated T cells, B cells, macrophages, mast cells, endothelial cells, and fibroblasts, in response to cytokine of immune and inflammatory stimuli. Besides granulocyte-macrophage progenitors, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. On mature hematopoietic, monocytes/macrophages and eosinophils. Human Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) can induce human endothelial cells to migrate and proliferate. Additionally, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) can stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma, and adenocarcinoma cell lines.
Synonyms Granulocyte Macrophage Colony Stimulating Factor; CSF-2; MGI-1GM; GM-CSF; Pluripoietin-alpha; Molgramostin; Sargramostim; MGC131935; MGC138897

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.